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Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myx-
omatous mitral valve disease (MMVD) and cardiomegaly have not been described.
Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart
size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly.
To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF.
Animals: Three hundred and fifty-four dogs with MMVD and cardiomegaly.
Materials and Methods: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4–0.6 mg/kg/d) or
placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points
(day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic
variables and time to CHF or CRD were explored.
Results: At day 35, heart size had reduced in the pimobendan group: median change in (D) LVIDDN 0.06 (IQR: 0.15
to +0.02), P < 0.0001, and LA:Ao 0.08 (IQR: 0.23 to +0.03), P < 0.0001. Reduction in heart size was associated with
increased time to CHF or CRD. Hazard ratio for a 0.1 increase in DLVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1
increase in DLA:Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar.
Conclusions and Clinical Importance: Pimobendan treatment reduces heart size. Reduced heart size is associated with
improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo.
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The “Evaluation of Pimobendan In dogs with Car-diomegaly caused by preclinical mitral valve dis-
ease” (EPIC) study1 was a multicenter, blinded,
randomized, placebo-controlled clinical trial evaluating
the effect of pimobendan in delaying the onset of clini-
cal signs in dogs with cardiac enlargement secondary to
myxomatous mitral valve disease (MMVD). The main
findings have been published and demonstrated a signif-
icant benefit of treatment in prolonging the time to the
primary endpoint, which was a composite of the onset
of congestive heart failure (CHF) or cardiac-related
death.1 Although the beneficial effects of the treatment
were clear, none of the longitudinal effects of the drug
on clinical, radiographic, and echocardiographic vari-
ables have yet been reported in dogs with preclinical
MMVD.
Dogs with MMVD go through various stages of the
disease.2 In the first stage of the disease (stage B1), dogs
have insufficiency of their mitral valve, but there is no
evidence of cardiac enlargement. In those dogs in which
the disease progresses, heart size enlarges as a conse-
quence of the left-sided volume overload. Dogs with
cardiac enlargement that have not yet developed signs
of CHF are considered to be in stage B2. Signs of CHF
develop in some dogs, typically after a period during
which the heart undergoes progressively more rapid
enlargement.3–5
Dogs with increased heart size and with the most
rapid rate of change in heart size are at the greatest risk
of development of CHF.4,5 Increased heart size in dogs
at all stages is predictive of an increased risk of cardiac-
related death.6–8
Previous studies of dogs with cardiomegaly secondary
to heart disease have demonstrated a reduction in
heart size associated with the administration of
pimobendan.9–12 In Doberman pinschers with preclinical
dilated cardiomyopathy (DCM), the degree to which the
heart size reduced in response to the administration of
pimobendan was predictive of a decreased likelihood of
experiencing the primary endpoint of the study, which
was a composite of CHF or cardiac-related death.11
Longitudinal effects of pimobendan treatment have
been described in dogs with stage C MMVD9 but have
not been reported in dogs with stage B disease. Some
dogs show subtle signs associated with their cardiac dis-
ease before overt signs of CHF develop. Such signs
might include cough attributable to cardiomegaly,13
intolerance of exercise, increasing resting respiratory
rate, and weight loss. No previous prospective study
has described the change in clinical signs and other vari-
ables in a large cohort of dogs as they progress from
stage B2 to stage C MMVD. Of the dogs enrolled in
the EPIC study, 135 were confirmed to have developed
CHF,1 and this population allows us to characterize the
changes that occur as dogs progress from a preclinical
stage of the disease, stage B2, into CHF.
The aims of this study were to investigate, in a popu-
lation of dogs with stage B2 MMVD, the influence of
treatment with pimobendan on clinical, radiographic,
and echocardiographic variables in both the short
and long term, and whether short-term changes in
echocardiographic variables might predict the time to
the onset of CHF or cardiac-related death. Addition-
ally, we aimed to describe a large group of dogs as they
progress from stage B2 to stage C MMVD and to
determine whether dogs that develop CHF while receiv-
ing pimobendan differ from those that develop CHF
while receiving placebo.
Materials and Methods
Trial Design
The EPIC trial was a prospective multicenter, blinded, random-
ized, placebo-controlled study. Complete and detailed description
of the study has been published.1
Dogs
Enrollment Criteria
Dogs were eligible for participation in the study provided that
the owner had given informed consent.
Abbreviations:
2D 2-dimensional
ALT alanine aminotransferase
AUC area under the curve
BCS body condition score
BPM beats per minute
CHF congestive heart failure
CI confidence intervals
CKCS Cavalier King Charles Spaniels
CRD cardiac-related death
ECG electrocardiogram
EPIC Evaluation of Pimobendan in dogs with Cardiomegaly
Caused by Preclinical Mitral Valve Disease
F female
FS% fractional shortening
FS female spayed
GPT glutamic-pyruvate transaminase
HR hazard ratio
IQR interquartile range
K+ potassium
LA/Ao left atrial-to-aortic ratio
LVIDd left ventricular internal diameter in diastole
LVIDDN normalized left ventricular internal diameter in diastole
LVIDs left ventricular internal diameter in systole
LVIDSN normalized left ventricular internal diameter in systole
MC male castrated
M male
MMVD myxomatous mitral valve disease
MR mitral regurgitation
Na+ sodium
NA not able to calculate
PCV packed cell volume
PP per protocol
SAP systolic arterial blood pressure
TPC total protein concentration
UK United Kingdom
USA United States of America
VHS vertebral heart sum
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To be eligible for inclusion, a dog had to be 6 years of age or
older, have a body weight ≥4.1 and ≤15 kg, have a characteristic
systolic heart murmur of moderate-to-high intensity (≥grade 3/6)
with maximal intensity over the mitral area, have echocardio-
graphic evidence of advanced MMVD defined as characteristic
valvular lesions of the mitral valve apparatus, mitral regurgitation
(MR) on the color Doppler echocardiogram, and have echocardio-
graphic and radiographic evidence of cardiomegaly defined as a
left atrial-to-aortic root ratio (LA/Ao) ≥1.6 measured in a short-
axis view,14 body weight normalized left ventricular internal diam-
eter in diastole (LVIDDN)15 ≥1.7, and a vertebral heart sum
(VHS) >10.5.16
Exclusion Criteria
Dogs were excluded from the study if they had any of the fol-
lowing: known clinically important systemic or other organ-related
disease that was expected to limit the dog’s life expectancy or
required chronic administration of cardiovascular medication pre-
cluded as part of the trial. Dogs with hypothyroidism could be
included provided the investigator deemed them clinically stable
on treatment. Dogs with current or previous evidence of cardio-
genic pulmonary edema, pulmonary venous congestion or both,
cardiac disease other than MMVD, clinically significant supraven-
tricular, ventricular tachyarrhythmias or both (ie, requiring antiar-
rhythmic treatment), or evidence of pulmonary hypertension
considered to be clinically relevant (RV:RA pressure gradient
>65 mmHg) were excluded. Dogs with a history of chronic or
recent administration (>14 days of duration or within 30 days of
intended enrollment) of any precluded medication were excluded.
Dogs that were pregnant or lactating were not eligible for enroll-
ment. In the event that before study enrollment, if a dog had
received short-term treatment (<14 days) with a precluded agent,
but was no longer receiving treatment and had not received it
within 30 days of intended enrollment, then the dog was eligible
for inclusion.
Details of study sites, randomization and blinding, concomitant
treatment, and data management have previously been described.1
Trial Medication
Pimobendan veruma was administered PO at a target dose of
0.4–0.6 mg/kg/d as per registered label instructions in most coun-
tries where the product was licensed. Placebo was administered in
a similar manner. Placebo and verum tablets and packaging con-
tainers were visually identical.
Schedule of Events
Before inclusion, a case history was taken for each dog. The
dog then underwent a physical examination, echocardiography,
thoracic radiography, and routine hematology and blood biochem-
istry (performed at laboratories local to each investigator) with a
minimum database consisting of packed cell volume (PCV), ala-
nine aminotransferase (ALT), glutamic pyruvate transaminase
(GPT), total protein concentration (TPC), creatinine, potassium
(K+), and sodium (Na+) concentrations. Re-examinations were
scheduled at day 35 and approximately 4 months after inclusion.
Thereafter, the dogs were scheduled for re-examination every
4 months. Details of examinations that were undertaken on each
visit are provided in Table 1.
Clinical Evaluation
At inclusion, dog characteristics such as breed, age, sex, and
neutering status were noted. The body weight, body condition
score (BCS), rectal temperature, and respiratory rate were mea-
sured at each visit.
Echocardiography
Echocardiography was performed on unsedated dogs. The fol-
lowing measurements were each taken over at least 3 cardiac
cycles, and the mean was recorded as follows: the LA/Ao obtained
from the right parasternal short-axis 2D view as previously
described,14 the left ventricular internal diameter at end-diastole
(LVIDd), and left ventricular internal diameter at end-systole
(LVIDs) measured on the M-mode echocardiogram, obtained from
the right parasternal short-axis view.17 M-mode values were used
to derive the fractional shortening (FS%). Normalized
dimensions15 were calculated according to the following formulae:
normalized LVIDd (LVIDDN) = LVIDd(cm)/(BW (kg))0.294;
normalized LVIDs (LVIDSN) = LVIDs(cm)/(BW(kg))0.315.
Thoracic Radiography
Thoracic radiography was performed at inclusion, 8 months
after inclusion and every 8 months thereafter for as long as the
dog remained in the per-protocol (PP) population. It was also per-
formed at the time a dog was considered to have developed signs
of CHF. Right lateral and dorsoventral projections were used to
evaluate the thorax. Cardiac size was assessed by the VHS
method,9 and pulmonary edema and congestion were recorded,
when considered to be present, by the attending cardiologist.
Primary Endpoint
The primary endpoint was a composite of the development of
left-sided CHF verified by an endpoint committee, euthanasia for
a cardiac reason, or death presumed to be cardiac in origin. The
primary outcome variable of the study was the time period from
inclusion until the primary endpoint was reached.
Visit data for the day 35 visit were included in the analyses pro-
vided the dog was re-examined between 28 and 42 days (day
35  7 days) after initiation of treatment. Visit data for subse-
quent visits were included in between-group comparisons for each
visit providing the visit took place within 30 days of the scheduled
date of re-examination.
Quality of life variables were assessed at baseline by an ordinal
scoring system (Table S1). After baseline assessment of quality of
life variables, at each subsequent visit, owners were asked to score
the following characteristics on a 5-point scale (Table 2): appetite,
demeanor, exercise tolerance, fainting, respiratory effort, cough,
and nocturnal dyspnea/coughing.
Owners were also asked to measure resting respiratory rate
before every re-examination, and the average resting respiratory
rate during that period was noted. Instruction was provided to
owners who were advised to count the respiratory rate over one
minute within the week before each re-examination. Ideally, this
was performed on several days, and the average of the measure-
ments obtained was recorded as a single value at the correspond-
ing visit.
Statistical Methods
Any dog in the study population that was confirmed to have
met all inclusion criteria (and none of the exclusion criteria) was
included in the PP population until one of the following occurred:
The dog reached the primary endpoint, the dog was censored from
the primary endpoint analysis due to the occurrence of an event
that precluded continuation in that population, or the end of the
study was reached. All analyses described herein were conducted
on dogs that remained in the PP population.
For continuous variables that were measured at both baseline
and day 35, a “change from baseline” variable was created by sub-
tracting the value obtained at baseline from the day 35 value.
For every dog for which any of the clinical or radiographic
continuous variables (ie, body weight, rectal temperature, respira-
tory rate, owner-measured resting respiratory rate, heart rate, and
VHS) were measured on at least one additional visit after base-
line assessment (2 occasions after baseline for owner-measured
respiratory rate), a curve was constructed by plotting each data
point on a graph with the unit of measurement on the vertical
axis and time on the horizontal axis. The area under the curve
(AUC) averaged for the number of days between the first and
last observation was calculated, thus giving an average value for
that variable that incorporated all of the observations made and
was independent of the duration of time the dog remained in the
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study.18 These summary values were then compared between
treatment groups.
For comparison of quality of life characteristics between groups
at specific visits, dogs in each group were classified on an ordinal
scale to be improved (+1), unchanged (0), or deteriorated (1)
(Table 2).
For ordinal variables measured on the same scale at baseline
and all subsequent visits (ie, BCS, heart murmur intensity, and
heart disease class), dogs were classified as having increased (+1),
remained unchanged (0), or decreased (1).
Between-group comparisons of the change in ordinal variables
were undertaken at each scheduled visit up to the visit at which
fewer than 50% of dogs remained in each group.
For all continuous and ordinal variables, between-group com-
parisons were made by Mann-Whitney tests. For within-group
paired comparisons of all ordinal and continuous variables, the
Wilcoxon signed ranks test was used.
The results of multivariable Cox proportional hazards analysis
analyzing the association between treatment and clinical variables
measured at baseline and the time to the primary endpoint have
been described in this population.1 In this longitudinal analysis,
the effects of a change in echocardiographic variables on time to
the primary endpoint were explored by multivariable Cox propor-
tional hazards analysis. Separate multivariable models were con-
structed for each of 4 echocardiographic variables; LVIDDN,
LVIDSN, LA/Ao, and FS%. In each model, the baseline value of
the variable, the change from baseline at day 35, and the treatment
effect were entered as explanatory variables. Time to the primary
endpoint was the dependent variable. For each model, all dogs in
the PP population for which paired observations were available to
derive a value for the change from baseline at day 35 were entered
into each analysis. Dogs leaving the PP population for reasons
other than reaching the primary endpoint were right-censored at
the time of leaving the population. Variables entered into each
multivariable model were assessed for collinearity with other vari-
ables in the same model and to ensure that the proportional haz-
ards and linearity assumptions were met.
The threshold of significance was defined as P < 0.05. All anal-
yses were 2-tailed. Statistical analyses were performed with a com-
mercially available software program.b
Results
A flow diagram outlining the number of dogs in the
PP population in each group at different time points
and the number of dogs reaching the primary endpoint
is illustrated in Figure 1.
Relevant baseline characteristics of the 2 treatment
groups are summarized in Table 3.
Comparisons at Day 35
Between-group comparisons of quality of life vari-
ables as perceived by owners at day 35 showed that the
pimobendan and placebo groups were not significantly
different in the extent to which any of the quality of life
variables had changed (Table 4). Within-group compar-
isons in the pimobendan group showed the following
quality of life scores to have significantly improved:
appetite, demeanor, exercise tolerance, and cough
(Table 4). The scores for owner perceptions of demea-
nor and exercise tolerance were also significantly
improved in the placebo group (Table 4).
For the physical examination, diagnostic imaging,
and laboratory variables (Table 5), in the pimobendan
group, there were significant decreases in LVIDDN,
LA/Ao, LVIDSN, plasma Na+ concentration, and cre-
atinine. There was a significant increase in FS% in the
pimobendan group. In the placebo group, the only sig-
nificant change was a decrease in LA/Ao. Between-
group comparisons of the changes showed a signifi-
cantly greater change in FS% in the pimobendan
group, and greater reductions in LVIDDN, LA/Ao,
and LVIDSN in the pimobendan group (Fig 2a–d).
Prognostic Value of Change in LVIDDN, LA/Ao,
LVIDSN, and FS% Between Baseline and Day 35
(Multivariable Cox Proportional Hazard Analysis)
Changes in echocardiographic variables between base-
line and day 35 were significantly predictive of outcome
Table 1. Schedule of procedures undergone by animals remaining in the per-protocol population of the study at dif-
ferent examinations.
Day 0
Day 35
(7 days)
4 monthsa
(30 days) 8 monthsb Event
Questionnaire X X X X X
Physical examination X X X X X
Thoracic radiograph X X X
Echocardiography X X X
Hematology and
clinical chemistry
X X X
a4 months from day 0 and every 8 months thereafter.
b8 months from day 0 and every 8 months thereafter.
Table 2. Ordinal scoring system used for quality of life
observations; appetite, demeanor, exercise tolerance,
fainting, respiratory effort, cough, and nocturnal dysp-
nea/coughing.
Owner’s Perception of
Quality of Life
Ordinal Score
Ascribed
Summary Category
for Between-Group
Comparisons
Greatly improved 1 Improved
Score = +1Improved 2
Unchanged 3 Unchanged
Score = 0
Deteriorated 4 Deteriorated
Score = 1Severely deteriorated 5
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in all multivariable models, except for change in FS%
(Table 6). The hazard ratio (HR) for the treatment
effect remained comparably constant and significant in
all the models, except for the multivariable analysis
including LVIDSN and change in LVIDSN, where the
observed treatment effect was apparently reduced (and
no longer significant). The 4 multivariable Cox propor-
tional hazards models are summarized in Table 6. (A
Forest plot for each model is illustrated in Fig S1a–d.)
Proportional hazards and linearity assumptions were
not violated, and no pair of variables entered into the
same model showed unacceptable collinearity.
Effect of Treatment Over Time
The AUCs adjusted for number of days in the study
for: body weight, rectal temperature, respiratory rate,
owner-measured resting respiratory rate, heart rate, and
VHS for each study group are summarized and com-
pared between groups in Table 7. The median AUCs
adjusted for number of days in the study for respiratory
rate, heart rate, and VHS were significantly lower in the
group receiving pimobendan.
There were no consistent differences observed
between treatment groups in quality of life scores,
change in heart murmur intensity, change in heart dis-
ease stage, and change in BCS when they were com-
pared at each visit up to the scheduled visit at
24 months, although heart failure score was worse at
20 months, and respiratory effort score was worse at
24 months in the placebo group (Table S2).
Comparison of Groups at the Onset of CHF
At the onset of CHF, there were no significant differ-
ences between treatment groups for any of the physical
examination, diagnostic imaging, or laboratory vari-
ables recorded (Table 8). For all dogs that went on to
develop CHF, there was, with the exception of serum
Na+, K+, and PCV, a significant change from baseline
to the onset of CHF in both the pimobendan and pla-
cebo group in all of the continuous clinical, diagnostic
imaging, and laboratory variables recorded. The magni-
tude of the change from baseline of these variables for
dogs from both groups combined is summarized in
Table 9. Likewise, there was a significant worsening of
quality of life variables, BCS, and heart murmur inten-
sity in their score as all dogs progressed from baseline
to CHF (Table 10). Only the difference in change in
exercise tolerance was significantly different between
groups, with a greater number of dogs in the pimoben-
dan group experiencing deterioration in exercise toler-
ance at the onset of CHF (Table 10).
Discussion
Our study has demonstrated a number of changes in
dogs with preclinical MMVD administered pimobendan,
Number of dogs enrolled 
and randomized
N = 360
Dogs not meeng 
inclusion criteria 
N = 4 
Pimobendan
N = 179
Placebo
N = 180
Dogs not meeng 
inclusion criteria
N = 1
Placebo
N = 176
Per Protocol 
populaon
Pimobendan
N = 178
Per Protocol 
populaon
Met primary endpoint
N = 88
• CHF = 76 
• Cardiac –related 
death or 
euthanasia = 12
Met primary endpoint
N = 74
• CHF = 59 
• Cardiac - related 
death or 
euthanasia = 15 
Dog removed from study 
by owner before 
receiving trial medicaon
N = 1
Dogs remaining in PP 
Populaon
• Day 35 = 169
• Visit 2 = 167
• Visit 3 = 149
• Visit 4 = 133
• Visit 5 = 119
• Visit 6 = 100
• Visit 7 = 86
Dogs remaining in PP 
Populaon
• Day 35 = 160
• Visit 2 = 154
• Visit 3 = 125
• Visit 4 = 105
• Visit 5 = 94
• Visit 6 = 76
• Visit 7 = 55
Fig. 1. A flowchart illustrating the randomization of the 360 dogs in the study, the numbers of dogs reaching the different components of
the primary endpoint in each treatment group, and the number of dogs in each treatment group remaining in the per-protocol population
at different scheduled visits. PP, per protocol; CHF, congestive heart failure.
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which are different to those that occur in dogs that
receive a placebo. Within the first month of treatment,
dogs in the pimobendan group demonstrated significant
reductions in 3 measures of heart size. The degree to
which heart size reduced was predictive of outcome with
a greater reduction in heart size associated with a pro-
longation of the time to the primary endpoint of the
study. Heart size was on average lower for the duration
of the study for dogs in the pimobendan group com-
pared to those in the placebo group. Quality of life was
perceived by owners to be improved after 1 month of
treatment for both the placebo and pimobendan groups.
At the onset of CHF, dogs receiving pimobendan were
indistinguishable from those receiving placebo, and
both groups had larger hearts and worse quality of life
compared to baseline.
There is a reduction in heart size in dogs with
MMVD9,10,12 and DCM11 administered pimobendan.
Earlier studies have only evaluated the effect of initia-
tion of pimobendan on dogs’ heart size after the onset
of heart failure in dogs with MMVD. This is therefore
the first study to show an effect of pimobendan in
Table 3. Baseline characteristics of the 2 treatment groups in the per-protocol population.
Variable
Treatment Groups
Pimobendan
n = 178
Placebo
n = 176
Dog characteristics Age (years) 9.0 (8.0–11.0) 9.0 (7.0–11.0)
Sex (M/F/MC/FS) (%) 36/6/75/61 (20/3/42/34) 35/12/66/63 (20/7/38/36)
Breed (CKCS/Dachshund/Miniature
Schnauzer/
Poodle/Yorkshire terrier/mixed
breed/other) (%)
77/12/5/4/0/26/54
(43/7/3/2/0/15/30)
84/9/8/4/8/19/44
(47/5/5/2/5/11/25)
Dose of test medication Dose pimobendan (mg/d) 0.49 (0.44–0.53) NA
Quality of life and
respiratory variables
(see Table S1 for details)
Appetite (decreased/normal/
increased) (%)
4/165/9 (2/93/5) 3/166/7 (2/94/4)
Demeanor (Alert/mildly
lethargic/moderately lethargic) (%)
175/3/0 (98/3/0) 168/7/1 (95/4/1)
Exercise tolerance
(very good/good/decreased) (%)
118/53/7 (66/30/4) 99/70/7 (56/40/4)
Fainting (none/rarely/occasional) (%) 175/3/0 (98/2/0) 170/4/2(97/2/1)
Respiratory effort
(normal/mildly increased/moderately
increased) (%)
172/5/1 (97/3/1) 164/10/2 (93/6/1)
Cough (none/occasional/
frequent/persistent) (%)
108/48/20/2 (61/27/11/1) 123/35/17/1 (70/20/10/1)
Nocturnal coughing
(none/slight/moderate) (%)
157/20/0 (89/11/0) 163/10/2 (93/6/1)
Physical examination variables Body weight (kg) 8.6 (6.9–10.6) 9.0 (7.1–10.5)
Body condition score
(underweight (1–3)/normal
(4–6)/overweight (7–9)) (%)
0/166/12 (0/93/7) 5/148/23 (3/84/13)
Rectal temperature (°C) 38.7 (38.4–39.1) 38.7 (38.4–39.0)
Heart rate (BPM) 124 (110–140) 122 (112–140)
Respiratory rate (breaths/min) 28 (24–36) 28 (24–36)
Heart murmur intensity (moderate
(grade 3–4)/severe (grade 5–6) (%)
133/45 (75/25) 133/43 (76/24)
Diagnostic imaging variables VHS 11.3 (10.9–12.0) 11.5 (11.0–11.9)
LVIDSN 1.03 (0.93–1.14) 1.02 (0.93–1.10)
LVIDDN 1.9 (1.8–2.1) 1.9 (1.8–2.0)
FS% (%) 43 (39–48) 44 (41–49)
LA/Ao 1.89 (1.73–2.10) 1.86 (1.72–2.06)
Laboratory variables Na+ (mmol/L) 148 (145–150) 148 (146–149)
K+ (mmol/L) 4.4 (4.1–4.8) 4.4 (4.1–4.7)
PCV (%) 44.0 (41.0–48.0) 44.0 (40.0–48.1)
Creatinine (lmol/L) 70.7 (60.0–88.4) 70.7 (61.0–82.2)
TPC (g/L) 65 (61–69) 66 (62–70)
GPT (ALT) (U/L) 43 (29–68) 42 (30–66)
ALT, alanine aminotransferase; BCS, body condition score; BPM, beats per minute; CKCS, Cavalier King Charles Spaniels; F, female;
FS, female neutered; FS%, fractional shortening; GPT, glutamic-pyruvate transaminase; K+, potassium concentration; LA/Ao, left atrial-
to-aortic root ratio; LVIDd, left ventricular internal diameter in diastole; LVIDDN, normalized left ventricular internal diameter in dias-
tole; LVIDs, left ventricular internal diameter in systole; LVIDSN, normalized left ventricular internal diameter in systole; M, male; MN,
male neutered; Na+, sodium concentration; PCV, packed cell volume; TPC, total protein concentration; VHS, vertebral heart sum.
Continuous variables are reported as median (interquartile range). Categorical variables are reported as number (%).
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reducing the heart size of dogs with MMVD and car-
diac enlargement before the onset of clinical signs. The
reduction in heart size was evident by 3 different
indices: LVIDDN, LVIDSN, and LA/Ao. Similar
changes in left ventricular diameter have been shown in
Dobermans with preclinical DCM.11 There was also an
increase in the FS% of dogs receiving pimobendan. A
small but significant reduction in left atrial size (LA/
Ao) was also seen in the placebo group. One possible
explanation for this would be “regression to the mean.”
Regression to the mean can occur when a clinical mea-
surement must exceed a threshold in order for a patient
to be recruited to a study.19 Patients with “true” values
for the measurement just below the threshold but an
erroneously high measurement at the time of screening
will enter the study, whereas those with true values just
above the threshold with an erroneously low measure-
ment will not. On a second measurement, despite the
“true” value not having changed, if the measurement
made is more reflective of the true measurement, it will
appear to have fallen or “regressed to the mean.” In
this case, as LA/Ao was one of the more stringent entry
criteria, regression to the mean in some recruited
patients makes it appear as though the value has fallen
in the placebo group. Importantly the reduction in left
atrial size was significantly greater in the pimobendan
group compared to the placebo group (median 0.08
compared to 0.027), indicating that there was a true
treatment effect as well as any change attributable to
variation in measurement.
The change in echocardiographic variables at day 35
(7 days) was associated with outcome. Those dogs
that had greater reductions in LA/Ao, LVIDDN, and
LVIDSN tended to have longer periods before reaching
the primary endpoint of the study. This effect was inde-
pendent of the effect of pimobendan administration as
shown by the multivariable analyses, in which the
change in the echocardiographic variable was signifi-
cantly associated with outcome even when the effect of
pimobendan was included in the model. For instance,
a 0.1-unit increase in LA/Ao increased the risk of
reaching the primary endpoint by 14% (HR = 1.14). A
reduction in the LA/Ao by 0.1 units decreased the risk
to 100/1.14%,that is, 87.7% representing a 12.3%
reduction in risk. When the change in systolic diameter
was included in the multivariable model, it appeared to
diminish the effect of pimobendan administration to the
greatest extent, making it appear nonsignificant (HR
0.71 [95% CI 0.51–1.00] P = 0.051). The same phe-
nomenon was observed in the PROTECT study11 where
in a multivariable analysis, the inclusion of the change
in systolic diameter led to a widening of the 95% CI of
the estimate of the treatment effect resulting in a non-
significant P-value for the treatment effect. This might
indicate that the change in systolic diameter is an “in-
tervening variable”20 and therefore on the causal path-
way by which pimobendan mediates its favorable effect
on outcome. The administration of pimobendan brings
about a reduction in systolic diameter. If the reduction
in systolic diameter is one of the major ways in which
Table 4. Within-group paired comparisons and between-group unpaired comparisons of the change from baseline
to day 35 of various quality of life and physical examination variables.
Categorical Variables Treatment Group N Deteriorated Unchanged Improved
Within-Group Comparison
(Wilcoxon Signed Ranks)
Between-Group
Comparison
(Mann-Whitney)
Appetite Placebo 160 6 140 14 0.12 0.33
Pimobendan 169 5 144 20 0.0012
Demeanor Placebo 160 3 135 22 <0.0001 0.34
Pimobendan 169 2 138 29 <0.0001
Exercise tolerance Placebo 160 4 132 24 <0.0001 0.75
Pimobendan 169 3 144 22 <0.0001
Fainting Placebo 160 2 157 1 1.0000 0.65
Pimobendan 169 1 167 1 1.0000
Respiratory effort Placebo 160 3 148 9 0.15 0.75
Pimobendan 169 1 162 6 0.13
Cough Placebo 160 9 134 17 0.12 0.46
Pimobendan 169 6 143 20 0.0038
Nocturnal dyspnea or
cough
Placebo 160 3 152 5 0.73 0.65
Pimobendan 169 2 161 6 0.29
Body condition score Placebo 160 24 123 13 0.070 0.55
Pimobendan 169 24 127 18 0.36
Heart failure stage Placebo 160 – 157 3 0.25 0.76
Pimobendan 169 – 165 4 0.13
Decreased Unchanged Increased
Auscultation
(change in
murmur grade)
Placebo 160 12 130 18 0.28 0.22
Pimobendan 169 21 131 17 0.52
All P-values that appear in bold are < 0.05.
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pimobendan mediates its favorable effect (ie, it interve-
nes on the “causal pathway”) once the reduction in sys-
tolic diameter is taken into account in a multivariable
analysis, the association between treatment and the out-
come is no longer apparent. These findings add further
weight to the existing literature which suggests that, at
least in part, the benefit of pimobendan treatment in
canine heart disease is mediated through the reduction
in heart size that it brings about. This speculation about
a potential mechanism of action in dogs with MR is
supported by experimental findings in dogs with
induced MR which suggest that reduced heart size and
enhanced contractile function are associated with a
reduction in mitral regurgitant orifice area and therefore
reduced MR.21,22
The observed reduction in heart size appeared to be
maintained over the duration of the study with the
average heart size, as indicated by the AUC for the
VHS, of dogs in the pimobendan group being smaller
compared to dogs in the placebo group.
Change in quality of life variables did not differ sig-
nificantly between groups at day 35. Although there
were 2 quality of life variables, appetite and cough, that
appeared to improve significantly in the pimobendan
group and not the placebo group, between-group com-
parisons did not reveal significant differences between
groups. Both groups appeared to show a highly signifi-
cant (P < 0.0001) improvement in demeanor and exer-
cise tolerance at day 35, yet the difference between
groups was not significant. These observed changes sug-
gest a possible “placebo effect” with owners perceiving
improvement in their dogs because they believed they
were receiving medication. This observation emphasizes
the importance of including a placebo group in clinical
trials in which subjective judgments are made about
responses to treatment. Almost all the dogs recruited to
the study were perceived by their owners to be normal
at the time of entry to the study; for instance, 96% of
owners rated their dog’s exercise tolerance as good or
very good on entry to the study. It would therefore be
less likely that a difference in improvement between
groups could be shown given that the dogs were not
considered to be showing clinical signs as a consequence
of their disease. The absence of differences between
Table 5. Within-group paired comparisons and between-group unpaired comparisons of the change from baseline
to day 35 of physical examination, echocardiographic, and laboratory variables.
Continuous Variables
Treatment
Group N
Absolute Change from
Baseline Median
(Interquartile Range)
Within-Group
Comparison
(Wilcoxon
Signed Ranks)
Between-Group
Comparison
(Mann-Whitney)
Physical examination
variables
Body weight (kg) Placebo 159 0.00 (0.20 to +0.20) 0.90 0.86
Pimobendan 168 0.00 (0.20 to +0.20) 0.99
Rectal temperature (°C) Placebo 160 0.00 (0.30 to +0.30) 0.47 0.98
Pimobendan 164 0.00 (0.30 to +0.30) 0.80
Respiratory rate
(breaths/min)
Placebo 152 0.0 (4 to +6) 0.24 0.51
Pimobendan 154 0.0 (4 to +4) 0.60
Heart rate (BPM) Placebo 160 0.0 (10.0 to +12.0) 0.37 0.26
Pimobendan 169 0.0 (12.0 to +10.0) 0.32
Echocardiographic
variables
FS% (%) Placebo 160 0.00 (3.75 to +3.20) 0.55 <0.0001
Pimobendan 169 +2.00 (1.00 to +5.00) <0.0001
LVIDDN Placebo 159 +0.01 (0.07 to +0.07) 0.71 <0.0001
Pimobendan 168 0.06 (0.15 to +0.02) <0.0001
LA/Ao Placebo 160 0.027 (0.182 to +0.084) 0.036 0.0076
Pimobendan 169 0.080 (0.229 to +0.028) <0.0001
LVIDSN Placebo 159 +0.0144 (0.0722 to +0.0715) 0.33 <0.0001
Pimobendan 168 0.0614 (0.1555 to 0.0033) <0.0001
Laboratory variables Na+ (mmol/L) Placebo 159 0.000 (2.000 to +2.000) 0.82 0.21
Pimobendan 167 0.000 (2.000 to +1.000) 0.030
K+ (mmol/L) Placebo 159 0.000 (0.200 to +0.300) 0.24 0.24
Pimobendan 168 0.000 (0.300 to +0.200) 0.67
PCV (%) Placebo 158 0.000 (1.900 to +2.100) 0.17 0.59
Pimobendan 168 +0.500 (2.000 to +2.750) 0.060
Creatinine (lmol/L) Placebo 159 0.000 (8.840 to +8.840) 0.86 0.094
Pimobendan 168 0.000 (8.840 to +4.210) 0.014
TPC (g/L) Placebo 158 0.000 (2.000 to +2.500) 0.72 0.19
Pimobendan 168 +0.415 (2.000 to +4.000) 0.054
GPT (ALT) (U/L) Placebo 159 0.000 (6.000 to +8.000) 0.52 0.38
Pimobendan 168 0.000 (9.000 to +6.000) 0.48
ALT, alanine aminotransferase; BPM, beats per minute; FS%, fractional shortening; GPT, glutamic-pyruvate transaminase; K+, potas-
sium concentration; LA/Ao, left atrial-to-aortic root ratio; LVIDDN, normalized left ventricular internal diameter in diastole; LVIDSN,
normalized left ventricular internal diameter in systole; Na+, sodium concentration; PCV, packed cell volume; TPC, total protein concen-
tration; VHS, vertebral heart sum.
All P-values that appear in bold are < 0.05.
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groups may also be a reflection of the relatively crude
means of rating quality of life scores that were used, by
comparison to validated tools such as the FETCH
score.23
Two clinical variables that were seen to be lower in
the pimobendan group when compared to the placebo
group over the duration of the study by the AUC
method were the heart rate on physical examination
and the owner-measured resting respiratory rate. The
median AUC of resting respiratory rate was 2 breaths
per minute lower in the pimobendan group, and the
median AUC of heart rate was 6 beats per minute
lower. Given that higher heart rate and higher resting
respiratory rate tend to be associated with more
advanced MMVD6 and the onset of CHF,24 the lower
rates in dogs treated with pimobendan might be an
indication of improved stability of these dogs even
though they were considered to be preclinical at the
time of recruitment to the trial.
The magnitude of the differences observed in heart
rate, resting respiratory rate, and VHS between groups
as a consequence of treatment was considerably smaller
than the observed variability within the population. For
instance, the IQR for heart rate in the population as a
whole at baseline was 30 beats per minute, whereas the
difference observed between the medians for the AUCs
observed in the 2 treatment groups was only 6 beats per
minute. Thus, the changes were not sufficiently profound
to allow the treatment groups to be discriminated, or to
act as reliable indicators of a response to treatment in
individual dogs. Similarly, although the difference
observed between groups in the change in echocardio-
graphic variables at day 35 was statistically highly signif-
icant, the magnitude of the absolute changes was
relatively small (the median change was <7% of median
baseline values). The within-group variability of the
measured changes was relatively large, and the magni-
tude of the changes in the 2 groups overlapped consider-
ably (Fig 2). This means that individual dogs on
pimobendan could not be reliably discriminated from
those on placebo on the basis of the changes observed.
Not all dogs recruited to the EPIC study went on to
develop CHF; however, the relatively large number of
dogs (135 in total) that did develop CHF provides us
with an opportunity to describe the changes that occur
in a number of clinical, radiographic, and echocardio-
graphic variables as dogs develop heart failure. In par-
ticular, we have paired observations in dogs obtained at
baseline and at the time of onset of CHF. It is notable
that the 2 treatment groups did not differ significantly
in any of the measured characteristics at the onset of
CHF; among other characteristics, heart size, heart rate,
and respiratory rate were very similar in both groups at
that time. The similar heart size seen in both groups
suggests that by the onset of CHF, the heart size in
dogs receiving pimobendan had increased up to a level
A B
DC
Fig. 2. Four box and whiskers plots illustrating absolute values of the change in 4 different echocardiographic variables between baseline
and day 35 in the 2 different treatment groups for (A) fractional shortening, (B) normalized left ventricular internal diameter in diastole,
(C) left atrial-to-aortic ratio and (D) normalized left ventricular internal diameter in systole. The bold horizontal line indicates the median
change, the boxes extend from the 25th to the 75th percentile. The whiskers extend from the 2.5th to the 97.5th percentile. P-values are for
between-group comparisons by a Mann-Whitney test. D, change in; FS%, fractional shortening; LA/Ao, left atrial-to-aortic root ratio;
LVIDDN, normalized left ventricular internal diameter in diastole; LVIDSN, normalized left ventricular internal diameter in systole.
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comparable to that observed in the placebo group,
despite being, on average, lower for the duration of the
study as determined by the AUC comparison of VHS.
If there is a critical heart size for a dog, which when
reached is likely to be associated with the development
of signs of CHF, it is possible that reducing heart size
at the onset of treatment is one of the ways in which
pimobendan delays the onset of CHF. We know from
the main results of the EPIC study that dogs receiving
pimobendan take longer to develop CHF, which may
argue again in favor of the reduction in heart size being
one of the primary ways in which this effect is medi-
ated.
Our analysis also showed that a number of clinical
and quality of life variables change in dogs as they
develop CHF. In the population of dogs that developed
CHF, body weight and rectal temperature decreased.
Some of the biochemical variables also changed with
creatinine and ALT increasing (although the median
change for creatinine was zero) and total protein
decreasing. No change in electrolyte concentrations or
PCV was observed.
As might be expected, the quality of life variables
measured universally showed evidence of deterioration
at the onset of CHF with only the change in exercise
tolerance differing between groups (with more
pimobendan dogs showing evidence of deterioration).
There was also a reduction in BCS and an increase in
murmur intensity in both groups.
Limitations
The analyses described in this study are exploratory
analyses of longitudinal data acquired from dogs in a
randomized clinical trial. They do not relate directly to
the primary hypothesis of the original study and should
therefore be regarded as hypothesis generating. Statisti-
cal analyses are not corrected for multiple comparisons,
and therefore, P-values close to the threshold of signifi-
cance should be interpreted with caution. For many of
the more important conclusions of the study, for exam-
ple, the reduction in heart size after 35 days, the
P-values associated with the comparisons are <0.0001
and therefore very unlikely to represent a type I statisti-
cal error.
Comparing groups in longitudinal studies is challeng-
ing, particularly when the rate at which individuals
leave those groups is unequal, not at random and
potentially related to what is being measured.25 For
example, dogs with bigger hearts are more likely to be
missing from the PP population because they have met
the primary endpoint of the study. This unequal time
spent in the study and unequal numbers of observations
in the 2 groups can be partially compensated for by
methods such as the AUC method we employ.18 This
method is only likely to be appropriate for use with
continuous variables where the values can be meaning-
fully averaged. When variables such as the quality of
life variables we recorded are compared, such a method
is probably not appropriate. Comparing groups at indi-
vidual visits is problematic because lower numbers of
animals will be left in the group that meets the primary
endpoint of the study more quickly (in this study the
placebo group). This means that after a given point in
the study, those animals that remain are likely to be in
some way exceptional rather than being representative
of the population as a whole. For this reason, we did
not compare quality of life variables between groups
after 24 months when fewer than 50% of the dogs
remained in each group.
Comparing quality of life between groups is also
challenging because those dogs with a poor quality of
life are likely to have left the study through either hav-
ing met the primary endpoint or having been censored
from the PP population for another reason. These types
of events tended to occur sooner in the group receiving
placebo, as was reflected by the results of the time to
first event analysis we have already described1 and is
indicated by the lower number of dogs remaining in the
PP population in the placebo group. Thus, the popula-
tions being compared are those remaining in the study
that continue to have a good quality of life, and differ-
ences between groups are not observed as is seen in
Table S2. As acknowledged above, the method we used
for assessing quality of life was a relatively insensitive,
subjective, and unvalidated tool and may also have con-
tributed to the absence of observed differences between
Table 6. Multivariable Cox proportional hazards mod-
els exploring the effect of treatment, change in an
echocardiographic variable, and the value of the same
variable recorded at baseline on time to the primary
endpoint constructed for 4 echocardiographic variables;
LVIDDN, LA/Ao, LVIDSN, and FS%.
Hazard
Ratio
95% Confidence
Intervals of
Hazard Ratio P-Value
Change in LVIDDN model (n = 327)
Treatment (pimobendan) 0.64 0.46–0.90 0.010
LVIDDN (per 0.1 unit) 1.30 1.20–1.41 <0.0001
D LVIDDN
(per 0.1 unit change)
1.26 1.11–1.43 0.0003
Change in LA/Ao model (n = 329)
Treatment (pimobendan) 0.63 0.46–0.88 0.0060
LA/Ao (per 0.1 unit) 1.21 1.15–1.28 <0.0001
D LA/Ao
(per 0.1 unit change)
1.14 1.06–1.22 0.0002
Change in LVIDSN model (n = 327)
Treatment (pimobendan) 0.71 0.51–1.00 0.051
LVIDSN (per 0.1 unit) 1.07 0.97–1.18 0.16
D LVIDSN
(per 0.1 unit change)
1.22 1.05–1.41 0.0084
Change in FS% model (n = 329)
Treatment (pimobendan) 0.64 0.46–0.90 0.011
FS % (per 10 units) 1.47 1.16–1.85 0.0014
D FS%
(per 10 units change)
1.05 0.77–1.44 0.75
D, Change in; FS%, fractional shortening; LA/Ao, left atrial-to-
aortic root ratio; LVIDDN, normalized left ventricular internal
diameter in diastole; LVIDSN, normalized left ventricular internal
diameter in systole.
All P-values that appear in bold are < 0.05.
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Table 7. Comparison between groups of the areas under the curve averaged over the number of days in the study
for each dog for those continuous variables that were recorded regularly throughout the monitoring period and on
at least 2 occasions.
Continuous Variables Treatment Group N
Median AUC Adjusted for
Days in Study (IQR) Between-Group Comparison
Body weight (kg) Placebo 173 8.5 (6.9–10.4) 0.54
Pimobendan 176 8.8 (6.9–10.5)
Rectal temperature (°C) Placebo 173 38.6 (38.4–38.8) 0.53
Pimobendan 176 38.6 (38.4–38.8)
Respiratory rate (breaths/min) Placebo 170 32 (26–40) 0.49
Pimobendan 173 31 (26–38)
Owner-measured resting
respiratory rate (breaths/min)
Placebo 156 24 (20–28) 0.0051
Pimobendan 163 22 (19–26)
Heart rate (BPM) Placebo 173 130 (119–140) 0.038
Pimobendan 176 124 (115–137)
Vertebral heart score (VHS) Placebo 157 11.9 (11.4–12.4) 0.0009
Pimobendan 163 11.5 (11.0–12.2)
BPM, beats per minute; VHS, vertebral heart sum.
All P-values that appear in bold are < 0.05.
Table 8. Values of physical examination, diagnostic imaging, and laboratory variables for those dogs that devel-
oped congestive heart failure, measured at the time of onset of heart failure summarized for the 2 treatment groups.
Continuous Variables Treatment Group N Median Value at CHF and IQR
Between-Group
Comparison
Physical examination
variables
Body weight (kg) Placebo 73 8.7 (6.9–10.6) 0.96
Pimobendan 58 9.2 (7.1–10.0)
Rectal temperature (°C) Placebo 66 38.6 (38.3–38.8) 0.11
Pimobendan 56 38.4 (38.0–38.8)
Respiratory rate (breaths/min) Placebo 69 44 (40–58) 0.25
Pimobendan 52 50 (36–66)
Owner-measured resting
respiratory rate
(breaths/min)
Placebo 58 36 (30–50) 0.50
Pimobendan 50 39 (34–50)
Heart rate (BPM) Placebo 71 150 (140–162) 0.60
Pimobendan 58 150 (140–164)
Diagnostic imaging
variables
FS% (%) Placebo 67 46.6 (42.5–50.1) 0.63
Pimobendan 55 46 (42.0–53.8)
LVIDDN Placebo 67 2.26 (2.14–2.51) 0.94
Pimobendan 55 2.27 (2.14–2.47)
LA/Ao Placebo 67 2.41 (2.15–2.80) 1.00
Pimobendan 55 2.47 (2.17–2.71)
LVIDSN Placebo 67 1.16 (1.03–1.33) 0.62
Pimobendan 55 1.13 (0.98–1.36)
VHS Placebo 72 13.0 (12.2–13.5) 0.45
Pimobendan 59 12.8 (12.1–13.5)
Laboratory variables Na+ (mmol/L) Placebo 68 147.0 (145.4–150.0) 0.66
Pimobendan 55 147.0 (146.0–149.0)
K+ (mmol/L) Placebo 68 4.50 (4.25–4.80) 0.40
Pimobendan 52 4.50 (4.00–4.80)
PCV (%) Placebo 66 41.5 (37.4–48.0) 0.12
Pimobendan 50 44.0 (40.0–47.0)
Creatinine (lmol/L) Placebo 68 78.8 (61.9–90.0) 0.90
Pimobendan 52 79.6 (64.9–87.2)
TPC (g/L) Placebo 66 64.0 (58.0–70.0) 0.77
Pimobendan 52 66.0 (60.5–68.0)
GPT (ALT) (U/L) Placebo 62 52.5 (35.0–77.0) 0.68
Pimobendan 51 54.0 (34.0–95.0)
ALT, alanine aminotransferase; BPM, beats per minute; FS%, fractional shortening; GPT, glutamic-pyruvate transaminase; K+, potas-
sium concentration; LA/Ao, left atrial-to-aortic root ratio; LVIDDN, normalized left ventricular internal diameter in diastole; LVIDSN,
normalized left ventricular internal diameter in systole; Na+, sodium concentration; PCV, packed cell volume; TPC, total protein concen-
tration; VHS, vertebral heart sum.
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groups. Having acknowledged these weaknesses in the
method of measurement, it was still possible by this
method for us to show a clear deterioration in quality
of life associated with the onset of CHF.
Conclusions
In dogs with preclinical MMVD, pimobendan treat-
ment results in a smaller heart size both in the short
Table 9. Change from baseline to the onset of heart failure for values of physical examination, diagnostic imaging,
and laboratory variables for those dogs that developed congestive heart failure summarized for the population as a
whole.
Continuous Variables N
Absolute Change from Baseline
Median (Interquartile Range) Comparison to Baseline
Physical examination variables Body weight (kg) 131 0.30 (0.7 to 0.1) <0.001
Rectal temperature (°C) 122 0.3 (0.7 to 0.1) <0.001
Respiratory rate (breaths/min) 118 16 (4–29) <0.001
Heart rate (BPM) 129 22 (8–38) <0.001
Diagnostic imaging variables FS% (%) 122 2.6 (2.6 to 7.7) 0.003
LVIDDN 122 0.35 (0.14–0.49) <0.001
LA/Ao 122 0.47 (0.24–0.75) <0.001
LVIDSN 122 0.13 (0.04 to 0.27) <0.001
VHS 131 1.3 (0.80–1.9) <0.001
Laboratory variables Na+ (mmol/L) 120 0.00 (3.0 to 2.0) 0.24
K+ (mmol/L) 119 0.10 (0.20 to 0.40) 0.067
PCV (%) 115 1.0 (3.9 to 3.0) 0.095
Creatinine (lmol/L) 119 0.0 (8.8 to 17.7) 0.018
TPC (g/L) 116 2.0 (5.5 to 3.0) 0.027
GPT (ALT) (U/L) 112 10.0 (6.0 to 43.0) <0.001
ALT, alanine aminotransferase; BPM, beats per minute; FS%, fractional shortening; GPT, glutamic-pyruvate transaminase; K+, potas-
sium concentration; LA/Ao, left atrial-to-aortic root ratio; LVIDDN, normalized left ventricular internal diameter in diastole; LVIDSN,
normalized left ventricular internal diameter in systole; Na+, sodium concentration; PCV, packed cell volume; TPC, total protein concen-
tration; VHS, vertebral heart sum.
All P-values that appear in bold are < 0.05.
Table 10. A summary of the number of dogs in each group that experienced a change in various clinical variables
at the time of the onset of congestive heart failure.
Categorical Variables Treatment Group N Deteriorated Unchanged Improved
Within-Group Paired
Longitudinal Comparisons
(Wilcoxon signed ranks)
Between-Group
Comparison
(Mann-Whitney)
Appetite Placebo 69 25 44 0 <0.0001 0.26
Pimobendan 57 27 29 1
Demeanor Placebo 69 41 28 0 <0.0001 0.45
Pimobendan 57 38 18 1
Exercise tolerance Placebo 69 41 28 0 <0.0001 0.020
Pimobendan 57 45 12 0
Fainting Placebo 69 14 55 0 <0.0001 0.52
Pimobendan 57 9 48 0
Respiratory effort Placebo 69 55 14 0 <0.0001 0.074
Pimobendan 57 52 5 0
Cough Placebo 69 60 6 3 <0.0001 0.82
Pimobendan 57 50 6 1
Nocturnal dyspnea
or cough
Placebo 67 46 21 0 <0.0001 0.76
Pimobendan 56 37 19 0
Decreased Unchanged Increased
Body condition score Placebo 72 26 37 9 0.0002 0.84
Pimobendan 58 21 28 9
Heart murmur intensity Placebo 72 8 30 34 <0.0001 0.17
Pimobendan 58 2 23 33
P-values for paired comparisons with the same characteristics recorded from the same dogs at baseline are given in the penultimate column.
All P-values that appear in bold are < 0.05.
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and long term. The degree to which heart size reduces
in the short term is predictive of outcome with a greater
reduction in heart size associated with a prolongation
of the time to CHF or cardiac-related death. In particu-
lar, the therapeutic benefit of pimobendan appears to
be associated with the reduction in LV end-systolic
dimension. There were no consistent differences
observed between treatment groups in quality of life
variables, either in the short or long term as might be
expected in a study of dogs with preclinical disease
where deterioration in quality of life often signified
reaching the primary endpoint or resulted in censoring.
At the onset of CHF, dogs treated with pimobendan
were indistinguishable from those receiving placebo
showing clear evidence of a deterioration in quality of
life and significant changes in a number of clinical,
diagnostic imaging, and laboratory variables.
Footnotes
a Vetmedin 2.5 mg chewable tablets
b SAS Version 8.2; SAS Institute Inc., Cary, NC, USA
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